BIO's BATTLE TO DELETE BREAKTHROUGH DRUGS COUNCIL FROM CLINTON PLAN
BIO's BATTLE TO DELETE BREAKTHROUGH DRUGS COUNCIL FROM CLINTON PLAN goes to the House Energy & Commerce/Health Subcommittee and Science/Technology Subcommittee during the first two weeks of February as the push to enact health care reform legislation heats up in Congress. Biotechnology Industry Organization President Carl Feldbaum noted at a Jan. 18 "Biotech Tuesday" briefing that the industry association is "focusing now on the Energy & Commerce Committee because they will have [President Clinton's Health Security Act] first, and they will have a significant impact on it."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth